Mannkind CORP 10-Q quarterly reports

MannKind Corporation reports increased total revenues for Q3 and 9M 2025, driven by product sales, collaborations, and royalties, alongside the strategic acquisition of scPharmaceuticals Inc. and an impairment loss on its Thirona investment.

MannKind Corporation achieved net income in the second quarter of 2025, driven by strong royalty revenue from Tyvaso DPI and growth in Afrezza sales, while significantly bolstering its liquidity with a new $500 million credit facility from Blackstone.

MannKind Corporation announces increased revenue for Q1 2025, driven by collaborations, services, and royalties, while managing expenses and maintaining a positive income from operations.

MannKind Corporation achieved a profitable third quarter in 2024, driven by significant revenue increases from product sales, collaborations, and royalties.

MannKind Corporation's Q2 2024 results show a complex picture with strong revenue growth driven by collaborations and royalties, but also increased expenses and a net loss.

MannKind Corporation achieved a profitable first quarter in 2024, driven by increased collaboration revenue and royalties from Tyvaso DPI sales, alongside growth in Afrezza revenue.